Brorson Kurt, De Wit Christina, Hamilton Elizabeth, Mustafa Mehnaz, Swann Patrick G, Kiss Robert, Taticek Ron, Polastri Gian, Stein Kathryn E, Xu Yuan
Division of Monoclonal Antibodies, Center for Biologics Evaluation and Research, Food and Drug Administration, 8800 Rockville Pike, Bethesda, Maryland 20892, USA.
Biotechnol Bioeng. 2002 Nov 5;80(3):257-67. doi: 10.1002/bit.10366.
Cell culture process changes (e.g., changes in scale, medium formulation, operational conditions) and cell line changes are common during the development life cycle of a therapeutic protein. To ensure that the impact of such process changes on product quality and safety is minimal, it is standard practice to compare critical product quality and safety attributes before and after the changes. One potential concern introduced by cell culture process improvements is the possibility of increased endogenous retrovirus expression to a level above the clearance capability of the subsequent purification process. To address this, retrovirus expression was measured in scaled down and full production scaled Chinese hamster ovary (CHO) cell cultures of four monoclonal antibodies and one recombinant protein before and after process changes. Two highly sensitive, quantitative (Q)-PCR-based assays were used to measure endogenous retroviruses. It is shown that cell culture process changes that primarily alter media components, nutrient feed volume, seed density, cell bank source (i.e., master cell bank vs. working cell bank), and vial size, or culture scale, singly or in combination, do not impact the rate of retrovirus expression to an extent greater than the variability of the Q-PCR assays (0.2-0.5 log(10)). Cell culture changes that significantly alter the metabolic state of the cells and/or rates of protein expression (e.g., pH and temperature shifts, NaButyrate addition) measurably impact the rate of retrovirus synthesis (up to 2 log(10)). The greatest degree of variation in endogenous retrovirus expression was observed between individual cell lines (up to 3 log(10)). These data support the practice of measuring endogenous retrovirus output for each new cell line introduced into manufacturing or after process changes that significantly increase product-specific productivity or alter the metabolic state, but suggest that reassessment of retrovirus expression after other process changes may be unnecessary.
在治疗性蛋白质的开发生命周期中,细胞培养工艺变更(例如规模、培养基配方、操作条件的变化)以及细胞系变更很常见。为确保此类工艺变更对产品质量和安全性的影响降至最低,在变更前后比较关键产品质量和安全性属性是标准做法。细胞培养工艺改进带来的一个潜在问题是内源性逆转录病毒表达可能增加到超过后续纯化工艺清除能力的水平。为解决这一问题,在工艺变更前后,对四种单克隆抗体和一种重组蛋白的小规模及全生产规模的中国仓鼠卵巢(CHO)细胞培养物中的逆转录病毒表达进行了测量。使用两种高度灵敏的基于定量(Q)-PCR的检测方法来测量内源性逆转录病毒。结果表明,主要改变培养基成分、营养物进料量、种子密度、细胞库来源(即主细胞库与工作细胞库)、小瓶大小或培养规模的细胞培养工艺变更,单独或组合起来,对逆转录病毒表达速率的影响程度不会超过Q-PCR检测的变异性(0.2 - 0.5 log₁₀)。显著改变细胞代谢状态和/或蛋白质表达速率的细胞培养变更(例如pH和温度变化、添加丁酸钠)会显著影响逆转录病毒合成速率(高达2 log₁₀)。在各个细胞系之间观察到内源性逆转录病毒表达的最大变化程度(高达3 log₁₀)。这些数据支持在引入生产的每个新细胞系或在显著提高产品特异性生产力或改变代谢状态的工艺变更后测量内源性逆转录病毒产量的做法,但表明在其他工艺变更后重新评估逆转录病毒表达可能没有必要。